Core Insights - Omada Health is launching a new prescribing capability for anti-obesity medications (AOM), including GLP-1s, as part of its weight health program, following a 53% year-over-year member growth as of Q3 [1][2] Group 1: New Offerings and Capabilities - The new prescribing capability aims to provide tailored support throughout the member journey, from prescription to ongoing medication management [2][3] - Omada's approach combines behavioral intelligence with clinical eligibility and health metrics to enhance prescribing decisions and care plans [2][3] - The new capability will be available in all 50 states, allowing for a nationally scalable model to support employers in managing AOM spend and outcomes [3][4] Group 2: Clinical Effectiveness and Outcomes - Omada's Enhanced GLP-1 Care Track has shown a 28% greater weight loss on average at 4 months compared to standard care [5] - Members in Omada's GLP-1 Care Track maintained an average weight change of just 0.8% 12 months post-medication discontinuation, significantly better than the typical 11-12% weight gain seen in clinical trials [5] Group 3: Strategic Positioning and Market Context - The launch aligns with the broader access to GLP-1 medications and reflects a shift in focus from access to effective and safe usage for long-term outcomes [2] - Omada Health aims to address challenges faced by payers and employers in obesity management by combining prescription capabilities with lifestyle support [4]